8. Huntington disease
197 clinical trials,   171 drugs   (DrugBank: 54 drugs),   82 drug target genes,   144 drug target pathways
Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2017-002471-25-GB (EUCTR) | 18/10/2018 | 04/08/2017 | An extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the study drug, RO7234292 (ISIS 443139), in patients who participated in prior investigational studies of RO7234292 | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 (ISIS 443139) IN HUNTINGTON'S DISEASE PATIENTS WHO PARTICIPATED IN PRIOR INVESTIGATIONAL STUDIES OF RO7234292 (ISIS 443139) | Early Manifest Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Code: Ro 723-4292/F02 INN or Proposed INN: n.a. Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx | F.Hoffmann La-Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 46 | Phase 1;Phase 2 | Canada;Germany;United Kingdom | ||
2 | EUCTR2017-002471-25-DE (EUCTR) | 10/01/2018 | 07/08/2017 | An extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the study drug, RO7234292 (ISIS 443139), in patients who participated in prior investigational studies of RO7234292 | An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington’s Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) | Early Manifest Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Code: Ro 723-4292/F02 INN or Proposed INN: n.a. Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx | F.Hoffmann La-Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 46 | Phase 2 | Canada;Germany;United Kingdom |